Get the Stockscreener App
0.912
3.84%
0.0337
After Hours:
.91
-0.002
-0.22%
Aprea Therapeutics Inc stock is traded at $0.912, with a volume of 131.27K.
It is up +3.84% in the last 24 hours and down -13.96% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$0.8783
Open:
$0.8925
24h Volume:
131.27K
Relative Volume:
1.40
Market Cap:
$6.38M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.2286
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
+2.47%
1M Performance:
-13.96%
6M Performance:
-47.59%
1Y Performance:
-78.79%
1-Day Range:
$0.8925
$1.00
1-Week Range:
$0.84
$1.00
52-Week Range:
$0.84
$4.65
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.912 | 6.14M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Market Recap: Will Aprea Therapeutics Inc stock reach all time highs in 2025 - moha.gov.vn
MSN Money - MSN
Aprea signals 2026 inflection as cancer trials advance and cash extends - MSN
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in December - Defense World
Aprea Therapeutics (NASDAQ:APRE) vs. Affymax (OTCMKTS:AFFY) Financial Survey - Defense World
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer - Quantisnow
Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE) - The Globe and Mail
Aprea Signals 2026 Inflection as Cancer Trials Advance and Cash Extends - MyChesCo
Can Aprea Therapeutics Inc. stock weather global recessionEnergy Sector Updates & Small Budget Capital Investment - bollywoodhelpline.com
Aprea Therapeutics (APRE) Stock Analysis Report | Financials & Insights - Benzinga
Will Aprea Therapeutics Inc. stock benefit from automationTrade Performance Summary & Weekly Return Optimization Alerts - Улправда
Why Aprea Therapeutics Inc. stock could rally in 20252025 Big Picture & Low Drawdown Investment Ideas - Улправда
Aprea Therapeutics (NASDAQ:APRE) Given New $5.00 Price Target at HC Wainwright - Defense World
Why retail investors favor Aprea Therapeutics Inc. stockTrade Volume Report & Free Reliable Trade Execution Plans - DonanımHaber
Aprea Therapeutics reports progress in cancer drug development By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains Aprea Therapeutics (APRE) Buy Recommendation - Nasdaq
APRE Analyst Forecasts - Quiver Quantitative
Aprea Therapeutics (APRE): HC Wainwright Maintains 'Buy' Rating, Lowers Price Target | APRE Stock News - GuruFocus
Aprea Therapeutics CEO issues letter to shareholders highlighting outlook for 2026 - marketscreener.com
Aprea Therapeutics reports progress in cancer drug development - Investing.com
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 - The Manila Times
Aprea Therapeutics Highlights Clinical Progress and Strategic Plans in Shareholder Update Letter - Quiver Quantitative
Aprea Therapeutics Earnings Notes - Trefis
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - MSN
Insider Buying: John Hamill Acquires Additional Shares of Aprea Therapeutics Inc (APRE) - GuruFocus
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Duey Marc buys $25,000 in shares By Investing.com - Investing.com Canada
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock - Investing.com India
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock By Investing.com - Investing.com South Africa
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock - Investing.com
Aprea Therapeutics Director Marc Duey Acquires 21,459 Shares - TradingView — Track All Markets
Dir Duey Buys 21,459 ($25K) Of Aprea Therapeutics Inc [APRE] - TradingView — Track All Markets
Aprea Therapeutics raises $3.1 million in private placement By Investing.com - Investing.com Canada
Aprea Therapeutics, Inc. announced that it expects to receive $3.055822 million in funding - marketscreener.com
Aprea Therapeutics raises $3.1 million in private placement - Investing.com
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Aprea Therapeutics (Nasdaq: APRE) prices $3.1M private placement to extend cash runway into Q1 2027 - Stock Titan
Aprea Therapeutics (NASDAQ: APRE) registers 219,242 shares under 2019 equity plan - Stock Titan
Aprea Therapeutics secures $3.1M in private placement - MSN
Why Aprea Therapeutics Inc. stock is seen as undervaluedMarket Weekly Review & Growth Focused Investment Plans - Newser
Aprea Therapeutics, Inc. (NASDAQ:APRE): Is Breakeven Near? - simplywall.st
How Aprea Therapeutics Inc. stock performs in rising dollar environmentJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - Newser
Head and Neck Cancer Therapeutics Market | Global Market Analysis Report2035 - Fact.MR
Is Aprea Therapeutics Inc a good long term investmentRSI Overbought/Oversold & Learn From the Strategies of Institutions - earlytimes.in
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen - MSN
Why Aprea Therapeutics Inc. stock could outperform in 2025July 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Aprea Therapeutics Inc. stock sustain free cash flow growthWatch List & Weekly Momentum Picks - newser.com
How supply chain issues affect Aprea Therapeutics Inc. stockEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
Is Aprea Therapeutics Inc. stock a top momentum play2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aprea Therapeutics Inc Stock (APRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Dec 10 '25 |
Buy |
1.17 |
5,000 |
5,825 |
27,733 |
| Gilad Oren | President/CEO |
Apr 03 '25 |
Buy |
1.84 |
5,500 |
10,110 |
345,620 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):